Zai Lab and argenx Receive NMPA Approval for Vygart Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its US partner argenx SE...
Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...
BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...
Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT
hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...
ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Viatris Reports Q3 2024 Global Sales of USD 3.8 Billion with a 5% YOY Decline
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter...
Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results...
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...
Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems
Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China,...
AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...
Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical technology company, has announced...
Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it...
J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab
Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...